fda semaglutide Approves Oral as the First Oral GLP-1 Pill Hims & Hers stock falls

Although there was no change in kidney function in this study, it further validates the possibility of FMT use in managing CKD

If the on-body injector was placed on the back of your arm, a caregiver must be available to monitor your on-body injector

Can, Adem, et al

Our goal is to empower you to achieve optimal brain health and improve your quality of life

Key findings from the Phase 2 trial included: Dose-dependent weight loss , with greater reductions observed at higher doses Significant improvements in waist circumference , blood pressure , and lipid profiles Reductions in fasting glucose and insulin resistance markers, though the clinical significance of these findings in people with type 2 diabetes requires further investigation Weight loss appeared to continue throughout the 48-week period without a clear plateau at the highest doses Whilst these results are encouraging, it is important to contextualise them appropriately

Many individuals prescribed these medications may have pre-existing risk factors for reflux, including obesity itself, which is a well-established independent risk factor for GORD